The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female patients who receive the palonosetron or not.
Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. In addition, cough suppression of remifentanil enables smooth extubation with reduced complications. However, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
45
Normal saline 2 mL, intravenous injection
Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine
Suwon, South Korea
optimal Ce of remifentanil
Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia
Time frame: From the end of surgery until the time of endotracheal extubation, about 20 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.